Ginsenoside Rb1 Alleviates Bleomycin-Induced Pulmonary Inflammation and Fibrosis by Suppressing Central Nucleotide-Binding Oligomerization-, Leucine-Rich Repeat-, and Pyrin Domains-Containing Protein Three Inflammasome Activation and the NF-κB Pathway

Drug Des Devel Ther. 2022 Jun 13:16:1793-1809. doi: 10.2147/DDDT.S361748. eCollection 2022.

Abstract

Purpose: Idiopathic pulmonary fibrosis is a chronic and irreversible fibrotic interstitial pneumonia of unknown etiology and therapeutic strategies are limited. Emerging evidence suggests that the continuous activation of the central nucleotide-binding oligomerization-, leucine-rich repeat-, and pyrin domain-containing protein 3 (NLRP3) inflammasome is involved in the pathogenesis of pulmonary fibrosis. Ginsenoside Rb1 (G-Rb1) is the most abundant component in the traditional Chinese herb ginseng and has anti-inflammatory and anti-fibrotic activities. The purpose of this study was to explore whether G-Rb1 exerts anti-inflammatory and anti-fibrotic activities in vivo and in vitro by suppressing the activation of the NLRP3 inflammasome and NF-κB pathway.

Methods: Forty-eight male C57BL/6 mice were randomly divided into four groups (n=12/group) as follows: control, bleomycin (BLM), BLM/G-Rb1, and G-Rb1. A pulmonary fibrosis model was developed via an intratracheal injection of BLM. Six mice from each group were euthanized on days 3 and 21. The degree of pulmonary fibrosis was examined by histological evaluation and assessing α-smooth muscle actin levels. THP-1 cells were differentiated into macrophages, and stimulated by lipopolysaccharide and adenosine triphosphate. Activation of the NLRP3 inflammasome and NF-κB pathway was determined by Western blotting. Interleukin-1 beta and interleukin-18 levels were measured by ELISA. MRC-5 cells were cultured in the conditioned medium of the treated macrophages, after which markers of myofibroblasts were determined by Western blotting.

Results: G-Rb1 ameliorated BLM-induced pulmonary inflammation and fibrosis in mice, and suppressed NLRP3 inflammasome activation and the NF-κB pathway in lung tissues. Moreover, interleukin-1 beta secreted after NLRP3 inflammasome activation in macrophages promoted fibroblast differentiation. G-Rb1 inhibited lipopolysaccharide- and adenosine triphosphate-induced NLRP3 inflammasome activation in macrophages and disturbed the crosstalk between macrophages and fibroblasts.

Conclusion: G-Rb1 ameliorates BLM-induced pulmonary inflammation and fibrosis by suppressing NLRP3 inflammasome activation and the NF-κB pathway. Hence, G-Rb1 is a potential novel therapeutic drug for idiopathic pulmonary fibrosis.

Keywords: G-Rb1; NLRP3 inflammasome; macrophages; pulmonary fibrosis.

MeSH terms

  • Adenosine Triphosphate / pharmacology
  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Bleomycin / adverse effects
  • Fibrosis
  • Ginsenosides
  • Idiopathic Pulmonary Fibrosis* / drug therapy
  • Inflammasomes / metabolism
  • Interleukin-1beta / metabolism
  • Leucine / therapeutic use
  • Lipopolysaccharides / pharmacology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • NF-kappa B / metabolism
  • NLR Family, Pyrin Domain-Containing 3 Protein / metabolism
  • Nucleotides / metabolism
  • Pneumonia* / chemically induced
  • Pneumonia* / drug therapy
  • Pneumonia* / metabolism
  • Pyrin Domain
  • Signal Transduction

Substances

  • Anti-Inflammatory Agents
  • Ginsenosides
  • Inflammasomes
  • Interleukin-1beta
  • Lipopolysaccharides
  • NF-kappa B
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • Nucleotides
  • Bleomycin
  • ginsenoside Rb1
  • Adenosine Triphosphate
  • Leucine

Grants and funding

The research was funded by the National Key Research and Development Program of China, key special projects of major chronic non-communicable disease prevention and control (2016YFC1304600), the Shandong Provincial Natural Science Foundation Youth Project (ZR2020QH289), and the National Natural Science Foundation of China youth project (82103803).